The human safety profile of 5-Amino-1MQ is essentially uncharacterized. There are no known human clinical trials, so there is no clinical record of side effects, tolerability, or long-term risk in people.[1]
Reviewed for accuracy · Last reviewed July 8, 2026In preclinical mouse studies, researchers reported that NNMT inhibitors reduced body weight without obvious adverse effects at the doses tested. That is reassuring for the animal models used, but it says little about safety in humans, where dose, duration, and individual factors differ substantially.
The honest position is that absence of reported harm in mice is not evidence of human safety. Anyone weighing an experimental, unapproved compound should factor in this large gap in the evidence and consult a clinician.
Because no human side-effect data exist, there is no validated management guidance. The safest course with an uncharacterized experimental compound is medical supervision.
This page is an independent educational reference and is not medical advice, and does not indicate any approval status for any use. Talk to a doctor before starting any compound.